FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1042-1053 October 4, 2001 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

More than 70 bacteria, viruses, parasites, and fungi are serious human pathogens.¹ Vaccines are available against some of these agents and are being developed against almost all the other bacteria and viruses and about half of the parasites. Table 1 lists infections for which there are now licensed vaccines and those for which a candidate vaccine has undergone a phase 3 clinical trial,² indicating that a vaccine will probably be licensed within 5 to 10 years.

View this table: [in this window] [in a new window]   Table 1. The Status of Vaccines against Some Human Pathogens.

 
Traditionally, attenuated vaccines were made by repeated passaging of the infectious agent in tissue culture or . . . [Full Text of this Article]

Efficacy of Some Childhood Vaccines

Safety of Vaccines

Global Vaccine Delivery

Immune Responses and the Control of Infections

Class I–Restricted CD8+ Cytotoxic T Cells

Regional Immunity

Evasion, Suppression, and Subversion of Immune Responses in Intracellular Infections

New Approaches to Vaccines

Production of Antigens and Antibodies in Transgenic Plants

Transcutaneous Immunization

Vaccine Development

Peptides, Subunits, and Adjuvants

Live-Agent Vaccines as Vectors of Other Vaccine Antigens

Immunization with DNA

Sequential Immunization

The Future of Vaccination

Infectious Diseases

Noncommunicable Diseases

            Autoimmune Diseases

            Cancer

            Alzheimer's Disease

Conclusions

Source Information

From the John Curtin School for Medical Research, Australian National University, Canberra, Australia.

Address reprint requests to Dr. Ada at the John Curtin School for Medical Research, Australian National University, Box 334, ACT 2601 Canberra, Australia.

References

This article has been cited by other articles:

• Savy, M., Edmond, K., Fine, P. E. M., Hall, A., Hennig, B. J., Moore, S. E., Mulholland, K., Schaible, U., Prentice, A. M. (2009). Landscape Analysis of Interactions between Nutrition and Vaccine Responses in Children. J. Nutr. 139: 2154S-2218S [Abstract] [Full Text]  
• Hall, S. N., Jacobson, S. H., Sewell, E. C. (2008). An Analysis of Pediatric Vaccine Formulary Selection Problems. Operations Research 56: 1348-1365 [Abstract]  
• Fishbein, D. B., Broder, K. R., Markowitz, L., Messonnier, N. (2008). New, and Some Not-so-New, Vaccines for Adolescents and Diseases They Prevent. Pediatrics 121: S5-S14 [Abstract] [Full Text]  
• Jaffe, D., Papadopoulos, E. B., Young, J. W., O'Reilly, R. J., Prockop, S., Kernan, N. A., Jakubowski, A., Boulad, F., Perales, M.-A., Castro-Malaspina, H., Small, T. N. (2006). Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 108: 2470-2475 [Abstract] [Full Text]  
• Kaminski, R. W., Turbyfill, K. R., Oaks, E. V. (2006). Mucosal adjuvant properties of the Shigella invasin complex.. Infect. Immun. 74: 2856-2866 [Abstract] [Full Text]  
• Aoyama, T., Kamata, K., Yamanaka, N., Takeuchi, Y., Higashihara, M., Kato, S. (2006). Characteristics of polyclonal anti-human nephrin antibodies induced by genetic immunization using nephrin cDNA. Nephrol Dial Transplant 21: 1073-1081 [Abstract] [Full Text]  
• Jeurissen, A., Billiau, A. D., Moens, L., Shengqiao, L., Landuyt, W., Wuyts, G., Boon, L., Waer, M., Ceuppens, J. L., Bossuyt, X. (2006). CD4+ T Lymphocytes Expressing CD40 Ligand Help the IgM Antibody Response to Soluble Pneumococcal Polysaccharides via an Intermediate Cell Type. J. Immunol. 176: 529-536 [Abstract] [Full Text]  
• O'Mahony, D., Kummar, S., Gutierrez, M. E. (2005). Non-Small-Cell Lung Cancer Vaccine Therapy: A Concise Review. JCO 23: 9022-9028 [Abstract] [Full Text]  
• Baley, J. E., Leonard, E. G. (2005). The Immunologic Basis for Neonatal Immunizations. NeoReviews 6: e463-e470 [Full Text]  
• Naylor, K., Li, G., Vallejo, A. N., Lee, W.-W., Koetz, K., Bryl, E., Witkowski, J., Fulbright, J., Weyand, C. M., Goronzy, J. J. (2005). The Influence of Age on T Cell Generation and TCR Diversity. J. Immunol. 174: 7446-7452 [Abstract] [Full Text]  
• Melanitou, E., Devendra, D., Liu, E., Miao, D., Eisenbarth, G. S. (2004). Early and Quantal (by Litter) Expression of Insulin Autoantibodies in the Nonobese Diabetic Mice Predict Early Diabetes Onset. J. Immunol. 173: 6603-6610 [Abstract] [Full Text]  
• McKenzie, B. S., Corbett, A. J., Johnson, S., Brady, J. L., Pleasance, J., Kramer, D. R., Boyle, J. S., Jackson, D. C., Strugnell, R. A., Lew, A. M. (2004). Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits local IgA responses. Int Immunol 16: 1613-1622 [Abstract] [Full Text]  
• Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., Plebanski, M. (2004). Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors. J. Immunol. 173: 3148-3154 [Abstract] [Full Text]  
• Castagliuolo, I., Sardina, M., Brun, P., DeRos, C., Mastrotto, C., Lovato, L., Palu, G. (2004). Clostridium difficile Toxin A Carboxyl-Terminus Peptide Lacking ADP-Ribosyltransferase Activity Acts as a Mucosal Adjuvant. Infect. Immun. 72: 2827-2836 [Abstract] [Full Text]  
• Bischof, F., Hofmann, M., Schumacher, T. N. M., Vyth-Dreese, F. A., Weissert, R., Schild, H., Kruisbeek, A. M., Melms, A. (2004). Analysis of Autoreactive CD4 T Cells in Experimental Autoimmune Encephalomyelitis after Primary and Secondary Challenge Using MHC Class II Tetramers. J. Immunol. 172: 2878-2884 [Abstract] [Full Text]  
• Mandic, A., Vujkov, T. (2004). Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?. Ann Oncol 15: 197-200 [Abstract] [Full Text]  
• Gibson, R. L., Burns, J. L., Ramsey, B. W. (2003). Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 168: 918-951 [Abstract] [Full Text]  
• Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., Michel, B. F., Boada, M., Frank, A., Hock, C. (2003). Subacute meningoencephalitis in a subset of patients with AD after A{beta}42 immunization. Neurology 61: 46-54 [Abstract] [Full Text]  
• Meissner, H. C., Pickering, L. K. (2002). Control of Disease Attributable to Haemophilus influenzae Type b and the National Immunization Program. Pediatrics 110: 820-823 [Full Text]  
• Mahalingam, S., Meanger, J., Foster, P. S., Lidbury, B. A. (2002). The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses. J. Leukoc. Biol. 72: 429-439 [Abstract] [Full Text]  
• Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N., Schuler, G. (2002). Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells. JEM 195: 1279-1288 [Abstract] [Full Text]  
• Barton, L. L., Ada, G. (2002). Immunology Series: Vaccines. NEJM 346: 864-866 [Full Text]  
• Mattner, F., Fleitmann, J.-K., Lingnau, K., Schmidt, W., Egyed, A., Fritz, J., Zauner, W., Wittmann, B., Gorny, I., Berger, M., Kirlappos, H., Otava, A., Birnstiel, M. L., Buschle, M. (2002). Vaccination with Poly-L-Arginine As Immunostimulant for Peptide Vaccines: Induction of Potent and Long-Lasting T-Cell Responses against Cancer Antigens. Cancer Res. 62: 1477-1480 [Abstract] [Full Text]  
• Zinkernagel, R. M. (2001). Maternal Antibodies, Childhood Infections, and Autoimmune Diseases. NEJM 345: 1331-1335 [Full Text]